Facid2%

Facid is an antibiotic (fusidane class) with established activity against Staphylococcus aureus, including many penicillin-resistant strains. It is indicated for:

• Established/approved use: Treatment of staphylococcal skin and soft tissue infections (e.g., boils, abscesses, wound infections, impetigo) caused by susceptible strains.
• Established/approved use: Treatment of staphylococcal bone and joint infections, including osteomyelitis and septic arthritis, where susceptibility has been confirmed.
• Guideline-supported/combination use: Serious staphylococcal infections such as endocarditis and bacteraemia, typically administered together with another antistaphylococcal antibiotic to reduce the risk of resistance developing during treatment.
• Adjunct use: As part of combination therapy in complicated or deep-seated staphylococcal infections when monotherapy is considered inadequate.

Facid should only be used for infections proven or strongly suspected to be caused by susceptible staphylococci; it is not effective against most Gram-negative organisms.

Each formulation of Sodium Fusidate contains sodium fusidate as the active ingredient, available as oral tablets, oral suspension (as fusidic acid), and intravenous infusion (as diethanolamine fusidate) depending on local product availability. Strength varies by dosage form and brand; refer to the specific product label for exact composition.

Facid is the sodium salt of fusidic acid, a narrow-spectrum, steroid-like antibiotic belonging to the fusidane class. Unlike topical fusidic acid preparations used for skin infections, Facid is formulated for systemic use (oral or intravenous) to treat deeper or more serious staphylococcal infections. It is well absorbed orally, distributes well into bone, soft tissue, and abscess fluid, and is metabolised primarily in the liver with biliary excretion.

Facid belongs to the fusidane class of antibiotics, a distinct chemical class structurally related to steroids but with no corticosteroid activity. It is classified as a narrow-spectrum, primarily anti-staphylococcal antibacterial agent.

Mechanism of Action

Sodium Fusidate inhibits bacterial protein synthesis by binding to elongation factor G (EF-G), preventing its release from the ribosome after translocation. This blocks the ribosomal cycle required for peptide chain elongation, resulting in bacteriostatic (and at higher concentrations, bactericidal) activity against susceptible staphylococci.

Pharmacokinetics

Sodium Fusidate is well absorbed after oral administration, is highly protein-bound (>95%), and penetrates well into bone, joint fluid, and infected soft tissue, which supports its use in osteomyelitis. It is extensively metabolised in the liver and eliminated mainly via bile into the faeces, with minimal renal excretion.

Oral tablets and suspension should be taken with or after food to minimise gastrointestinal upset. The intravenous infusion of Facid must be given slowly, diluted as directed, via a large vein to reduce the risk of local irritation or thrombophlebitis, and should be switched to oral therapy as soon as the patient's condition allows.

Statins (Clinically Significant)

Concurrent use of Facid with statins (particularly simvastatin and atorvastatin) is associated with an increased risk of severe, sometimes fatal, rhabdomyolysis. This combination should generally be avoided; statin therapy is typically withheld temporarily during systemic Facid treatment, and patients should be monitored closely for muscle pain, weakness, or dark urine.

Other Hepatotoxic Drugs

Concomitant use with other hepatotoxic medications may increase the risk of liver injury; liver function should be monitored when such combinations are unavoidable.

Warfarin and Other Anticoagulants

Facid may potentiate the anticoagulant effect of warfarin, increasing bleeding risk; more frequent INR monitoring is advised when used together.

Common

• Gastrointestinal upset (nausea, vomiting, diarrhoea, abdominal discomfort)
• Skin rash

Less Common but Clinically Important

• Hepatotoxicity: Dose-related liver enzyme elevation, especially with prolonged or high-dose systemic therapy; requires monitoring of liver function.
• Jaundice: Reversible cholestatic jaundice, more often associated with high-dose intravenous use.
• Local irritation or thrombophlebitis at the IV infusion site.

Patients should seek medical attention promptly if they notice yellowing of the skin/eyes, severe abdominal pain, or unusual bruising/bleeding.

Facid should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus, as safety data in human pregnancy are limited. Similarly, caution is advised during breastfeeding, since it is not fully established whether Facid passes into breast milk in clinically significant amounts. A physician should be consulted before use in pregnant or breastfeeding women.

Facid should be used with caution in patients with hepatic impairment, as it is extensively metabolised by the liver and carries a dose-related risk of hepatotoxicity; liver function should be monitored, especially during prolonged or high-dose systemic therapy. Facid is frequently used in combination with another antistaphylococcal antibiotic specifically to minimise the risk of resistance developing during monotherapy. Concurrent statin use should be avoided due to the risk of severe rhabdomyolysis (see Interactions). Take Facid exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice. Intravenous administration should be given slowly into a large vein to reduce local irritation.

Limited data exist on acute overdose with Facid. Overdose may be expected to worsen known adverse effects such as gastrointestinal upset or liver enzyme changes. In case of suspected overdose, seek immediate medical attention or contact a poison control centre; treatment is supportive, with monitoring of liver function as appropriate. Do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Hepatic Impairment

Facid should be used with caution in patients with hepatic impairment, with liver function monitoring during treatment, due to its hepatic metabolism and dose-related hepatotoxicity risk.

Renal Impairment

No significant dose adjustment is generally required in renal impairment, as Facid is eliminated predominantly via the biliary route rather than renally; however, caution is still advised in severe renal disease.

Elderly

No specific dose adjustment is established for elderly patients, but they should be monitored for hepatic and gastrointestinal adverse effects as with other adult patients.

Duration of treatment with Facid depends on the type and severity of infection. Skin and soft tissue infections are typically treated for 7–10 days, while bone and joint infections such as osteomyelitis often require several weeks (commonly 4–6 weeks or longer) of therapy, usually starting with combination antibiotic therapy. Treatment duration should always be determined by the prescribing physician based on clinical and, where relevant, microbiological response.

Sodium Fusidate is classified in the fusidane class of antibacterial agents, a narrow-spectrum group distinct from beta-lactams, macrolides, and other commonly used antibiotic classes.

Sodium Fusidate inhibits bacterial protein synthesis by binding to elongation factor G (EF-G) on the bacterial ribosome, blocking translocation during peptide chain elongation. This action is selective for susceptible staphylococci and does not affect human protein synthesis at therapeutic concentrations.

Facid can be used in children for susceptible staphylococcal infections, with dosing individualised by age and body weight (see Dosage and Administration). As with adults, liver function should be monitored during prolonged or high-dose therapy. Safety and efficacy in neonates have not been well established, and use in this age group should be guided by a specialist physician.